Helen Barraclough

1.3k total citations · 1 hit paper
24 papers, 928 citations indexed

About

Helen Barraclough is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Helen Barraclough has authored 24 papers receiving a total of 928 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Obstetrics and Gynecology. Recurrent topics in Helen Barraclough's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Lung Cancer Research Studies (6 papers). Helen Barraclough is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Lung Cancer Research Studies (6 papers). Helen Barraclough collaborates with scholars based in Australia, United States and China. Helen Barraclough's co-authors include Mauro Orlando, Ramaswamy Govindan, Alfonso Dueñas‐González, S. Beslija, Juan Carlos Alcedo, Luís Casanova, Shahid Hameed, Firuza D. Patel, Juan José Zarbá and Pittayapoom Pattaranutaporn and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Journal of Molecular Evolution.

In The Last Decade

Helen Barraclough

24 papers receiving 904 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix

2011 349 citations Alfonso Dueñas‐González, Juan José Zarbá et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helen Barraclough Australia	16	396	293	290	269	242	24	928
TS Shylasree India	16	537 1.4×	104 0.4×	299 1.0×	367 1.4×	396 1.6×	58	980
Amita Maheshwari India	19	727 1.8×	215 0.7×	429 1.5×	474 1.8×	438 1.8×	115	1.5k
Mary McCormack United Kingdom	20	723 1.8×	193 0.7×	334 1.2×	355 1.3×	355 1.5×	68	1.4k
Marilyn Huang United States	16	437 1.1×	87 0.3×	229 0.8×	115 0.4×	211 0.9×	96	802
Peter Blake United Kingdom	14	219 0.6×	207 0.7×	282 1.0×	108 0.4×	367 1.5×	21	862
Lawrence R. Ragard United States	13	242 0.6×	360 1.2×	253 0.9×	72 0.3×	194 0.8×	28	1.1k
Scott Kamelle United States	15	410 1.0×	97 0.3×	162 0.6×	141 0.5×	226 0.9×	23	733
Leslie Walton United States	13	348 0.9×	109 0.4×	191 0.7×	262 1.0×	271 1.1×	23	832
Wolfgang Janni Germany	22	296 0.7×	161 0.5×	350 1.2×	73 0.3×	201 0.8×	88	1.2k
François Planchamp France	14	853 2.2×	128 0.4×	277 1.0×	365 1.4×	450 1.9×	39	1.3k

Countries citing papers authored by Helen Barraclough

Since Specialization

Citations

This map shows the geographic impact of Helen Barraclough's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Barraclough with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Barraclough more than expected).

Fields of papers citing papers by Helen Barraclough

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Barraclough. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Barraclough. The network helps show where Helen Barraclough may publish in the future.

Co-authorship network of co-authors of Helen Barraclough

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Barraclough. A scholar is included among the top collaborators of Helen Barraclough based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Barraclough. Helen Barraclough is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Davis, Timothy M. E., David Bruce, Judith Finn, et al.. (2018). Temporal changes in the incidence and predictors of severe hypoglycaemia in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Obesity and Metabolism. 21(3). 648–657. 5 indexed citations

Ross, Glynis P., et al.. (2016). Relationship between depression and diabetes in pregnancy: A systematic review. World Journal of Diabetes. 7(19). 554–554. 47 indexed citations

Rajan, Narayan, Helen Barraclough, Tarun Puri, & Mauro Orlando. (2014). Cost effectiveness of concurrent gemcitabine and cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in stages IIB–IVA cervical cancer. Gynecologic Oncology Reports. 10. 36–37. 1 indexed citations

Yang, James Chih‐Hsin, Myung‐Ju Ahn, Kazuhiko Nakagawa, et al.. (2014). Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT. Cancer Research and Treatment. 47(3). 424–435. 2 indexed citations

Wu, Yi‐Long, Shun Lü, Ying Cheng, et al.. (2014). Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. Lung Cancer. 85(3). 401–407. 27 indexed citations

Simms, Lorinda, et al.. (2013). What a Clinician Ought to Know—Prognostic and Predictive Factors. 1 indexed citations

Pereira, José Rodrigues, Rebecca Cheng, Mauro Orlando, Joo-Hang Kim, & Helen Barraclough. (2013). Elderly Subset Analysis of Randomized Phase III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Drugs in R&D. 13(4). 289–296. 16 indexed citations

Simms, Lorinda, Helen Barraclough, & Ramaswamy Govindan. (2013). Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors. Journal of Thoracic Oncology. 8(6). 808–813. 30 indexed citations

Julka, Pramod Kumar, Raju Titus Chacko, Shona Nag, et al.. (2012). A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up. Breast Cancer. 20(4). 357–362. 4 indexed citations

10.

Dueñas‐González, Alfonso, et al.. (2012). Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine and cisplatin: Prognostic and predictive factors and the impact of disease stage on outcomes from a prospective randomized phase III trial. Gynecologic Oncology. 126(3). 334–340. 35 indexed citations

11.

Dueñas‐González, Alfonso, Juan José Zarbá, Firuza D. Patel, et al.. (2011). Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix. Journal of Clinical Oncology. 29(13). 1678–1685. 349 indexed citations breakdown →

12.

Davey, Peter, Neil Rajan, Helen Barraclough, et al.. (2011). PCN36 COST ANALYSIS, SAFETY, AND EFFICACY OF PEMETREXED/CISPLATIN COMPARED WITH BEVACIZUMAB/GEMCITABINE/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NSCLC IN RUSSIA. Value in Health. 14(3). A161–A161. 1 indexed citations

13.

Barraclough, Helen, Lorinda Simms, & Ramaswamy Govindan. (2011). Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios. Journal of Thoracic Oncology. 6(6). 978–982. 61 indexed citations

14.

Weston, Adèle, et al.. (2011). Histology as a treatment effect modifier in advanced non‐small cell lung cancer: A systematic review of the evidence. Respirology. 16(8). 1210–1220. 24 indexed citations

15.

Mitchell, Paul, et al.. (2011). Smoking History as a Predictive Factor of Treatment Response in Advanced Non–Small-Cell Lung Cancer: A Systematic Review. Clinical Lung Cancer. 13(4). 239–251. 23 indexed citations

16.

Paech, Daniel, Adèle Weston, Nick Pavlakis, et al.. (2010). A Systematic Review of the Interobserver Variability for Histology in the Differentiation between Squamous and Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(1). 55–63. 26 indexed citations

17.

Barraclough, Helen & Ramaswamy Govindan. (2010). Biostatistics Primer: What a Clinician Ought to Know: Subgroup Analyses. Journal of Thoracic Oncology. 5(5). 741–746. 33 indexed citations

18.

Dueñas‐González, Alfonso, Juan José Zarbá, Juan Carlos Alcedo, et al.. (2009). G3 A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix. European Journal of Cancer Supplements. 7(3). 7–7. 1 indexed citations

19.

Barraclough, Helen, et al.. (2008). Degree‐of‐spread artefact in the New South Wales Central Cancer Registry. Australian and New Zealand Journal of Public Health. 32(5). 414–416. 26 indexed citations

20.

Ersfeld, Klaus, Helen Barraclough, & Keith Gull. (2005). Evolutionary Relationships and Protein Domain Architecture in an Expanded Calpain Superfamily in Kinetoplastid Parasites. Journal of Molecular Evolution. 61(6). 742–757. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact